These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 18768470

  • 21. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors.
    de Winter JP, ten Dijke P, de Vries CJ, van Achterberg TA, Sugino H, de Waele P, Huylebroeck D, Verschueren K, van den Eijnden-van Raaij AJ.
    Mol Cell Endocrinol; 1996 Jan 15; 116(1):105-14. PubMed ID: 8822271
    [Abstract] [Full Text] [Related]

  • 22. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
    Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA.
    Endocrinology; 2008 Sep 15; 149(9):4589-95. PubMed ID: 18535106
    [Abstract] [Full Text] [Related]

  • 23. Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension.
    Guignabert C, Savale L, Boucly A, Thuillet R, Tu L, Ottaviani M, Rhodes CJ, De Groote P, Prévot G, Bergot E, Bourdin A, Howard LS, Fadel E, Beurnier A, Roche A, Jevnikar M, Jaïs X, Montani D, Wilkins MR, Sitbon O, Humbert M.
    Circulation; 2023 Jun 13; 147(24):1809-1822. PubMed ID: 37096577
    [Abstract] [Full Text] [Related]

  • 24. Crystal structures of the heparan sulfate-binding domain of follistatin. Insights into ligand binding.
    Innis CA, Hyvönen M.
    J Biol Chem; 2003 Oct 10; 278(41):39969-77. PubMed ID: 12867435
    [Abstract] [Full Text] [Related]

  • 25. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury.
    Oshima Y, Ouchi N, Shimano M, Pimentel DR, Papanicolaou KN, Panse KD, Tsuchida K, Lara-Pezzi E, Lee SJ, Walsh K.
    Circulation; 2009 Oct 20; 120(16):1606-15. PubMed ID: 19805648
    [Abstract] [Full Text] [Related]

  • 26. Heparin-mediated dimerization of follistatin.
    Walker RG, Kattamuri C, Goebel EJ, Zhang F, Hammel M, Tainer JA, Linhardt RJ, Thompson TB.
    Exp Biol Med (Maywood); 2021 Feb 20; 246(4):467-482. PubMed ID: 33197333
    [Abstract] [Full Text] [Related]

  • 27. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.
    Harrison CA, Chan KL, Robertson DM.
    Endocrinology; 2006 Jun 20; 147(6):2744-53. PubMed ID: 16527838
    [Abstract] [Full Text] [Related]

  • 28. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
    Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL.
    Endocrinology; 1996 Feb 20; 137(2):486-94. PubMed ID: 8593793
    [Abstract] [Full Text] [Related]

  • 29. Intracellular and extracellular control of activin function by novel regulatory molecules.
    Tsuchida K, Matsuzaki T, Yamakawa N, Liu Z, Sugino H.
    Mol Cell Endocrinol; 2001 Jun 30; 180(1-2):25-31. PubMed ID: 11451568
    [Abstract] [Full Text] [Related]

  • 30. Follistatin: essential role for the N-terminal domain in activin binding and neutralization.
    Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT.
    J Biol Chem; 2001 May 25; 276(21):17718-26. PubMed ID: 11279126
    [Abstract] [Full Text] [Related]

  • 31. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell.
    Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N, Titani K, Sugino H.
    J Biol Chem; 1993 Jul 25; 268(21):15579-87. PubMed ID: 8340384
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin.
    Glister C, Kemp CF, Knight PG.
    Reproduction; 2004 Feb 25; 127(2):239-54. PubMed ID: 15056790
    [Abstract] [Full Text] [Related]

  • 35. Structure and activation of pro-activin A.
    Wang X, Fischer G, Hyvönen M.
    Nat Commun; 2016 Jul 04; 7():12052. PubMed ID: 27373274
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice.
    Xia Y, Sidis Y, Schneyer A.
    Mol Endocrinol; 2004 Apr 04; 18(4):979-94. PubMed ID: 14739256
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.
    Cash JN, Rejon CA, McPherron AC, Bernard DJ, Thompson TB.
    EMBO J; 2009 Sep 02; 28(17):2662-76. PubMed ID: 19644449
    [Abstract] [Full Text] [Related]

  • 40. Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3.
    Saito S, Sidis Y, Mukherjee A, Xia Y, Schneyer A.
    Endocrinology; 2005 Dec 02; 146(12):5052-62. PubMed ID: 16150905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.